UPDATE: Janney Upgrades Concert Pharma To Buy 'on clinical progress with CTP-692, a program we believe has blockbuster potential that adds a Ph.2-ready program to a portfolio that includes Ph.2 CTP-543 and partnered program, Ph.3 AVP-786 (data 2H19)'